/NXL
NXL Stock - Nexalin Technology, Inc.
Healthcare|Medical - DevicesNASDAQ
$0.83+3.29%
+$0.03 (+3.29%) • Dec 19
37
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.8
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.91
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NXL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.82 – $0.84
TARGET (TP)$0.96
STOP LOSS$0.77
RISK/REWARD1:2.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.80
52W High$3.87
52W Low$0.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $168,721 | $110,748 | $1.32M | $144,065 | $242,914 |
| Gross Profit | $132,128 | $85,060 | $958,145 | $122,623 | $213,875 |
| Gross Margin | 78.3% | 76.8% | 72.5% | 85.1% | 88.0% |
| Operating Income | $-7,754,646 | $-5,696,296 | $-1,833,031 | $-6,018,601 | $-3,258,407 |
| Net Income | $-7,607,182 | $-4,648,709 | $-1,697,816 | $-6,078,004 | $-3,403,486 |
| Net Margin | -4508.7% | -4197.6% | -128.5% | -4218.9% | -1401.1% |
| EPS | $-0.83 | $-0.63 | $-0.23 | $-0.83 | $-0.47 |
Company Overview
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NXLBeat Rate
0%
Last 5 quarters
Avg Surprise
-56.7%
EPS vs Estimate
Beats / Misses
0/4
1 met exactly
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
-91.7%
$-0.23vs$-0.12
Q1 25
-133.3%
$-0.28vs$-0.12
Q2 25
-50.0%
$-0.15vs$-0.10
Q3 25
0.0%
$-0.10vs$-0.10
Q4 25
-8.3%
$-0.13vs$-0.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | $-0.12 | $-0.13 | -8.3% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.10 | $-0.10 | 0.0% | = MET |
Q2 2025 | May 13, 2025 | $-0.10 | $-0.15 | -50.0% | ✗ MISS |
Q1 2025 | Mar 14, 2025 | $-0.12 | $-0.28 | -133.3% | ✗ MISS |
Q4 2024 | Nov 8, 2024 | $-0.12 | $-0.23 | -91.7% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | — | $-0.17 | — | — |
Q2 2024 | May 10, 2024 | — | $-0.14 | — | — |
Q1 2024 | Mar 27, 2024 | — | $-0.10 | — | — |
Q4 2023 | Nov 13, 2023 | — | $-0.31 | — | — |
Q3 2023 | Aug 10, 2023 | — | $-0.11 | — | — |
Q2 2023 | May 10, 2023 | — | $-0.10 | — | — |
Q1 2023 | Mar 27, 2023 | — | $-0.11 | — | — |
Q1 2023 | Mar 2, 2023 | — | $-0.03 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.07 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.06 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.13 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.37 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.32 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.32 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.11 | — | — |
Latest News
Nexalin Technology Completes FDA Q-Submission Meeting Regarding Its Gen-2 SYNC Neurostimulation Console For Alzheimer's Disease
📈 PositiveBenzinga•Dec 3, 2025, 01:03 PM
Nexalin Technology Study On 15 Milliamp Neurostimulation Device Demonstrates Safety, Efficacy In Participant With Gambling Disorder, Alcohol Use Disorder
📈 PositiveBenzinga•Nov 18, 2025, 02:03 PM
Nexalin Technology Signs Exclusive Distribution Agreement With Carmi Masha Technologies To Advertise, Sell Nexalin's Gen-2 Console In Israel
📈 PositiveBenzinga•Nov 13, 2025, 02:21 PM
NXL stock has given up its prior gain. Nexalin Technology shares were trading higher after the company announced the FDA accepted its Q-submission for the Gen-2 SYNC device in Alzheimer's disease and dementia.
➖ NeutralBenzinga•Nov 5, 2025, 03:43 PM
Nexalin Technology shares are trading higher after the company announced the FDA accepted its Q-submission for the Gen-2 SYNC device in Alzheimer's disease and dementia.
📈 PositiveBenzinga•Nov 5, 2025, 01:34 PM
Nexalin Technology Announces FDA Acceptance Of Q-Submission For Gen-2 SYNC In Alzheimer's Disease And Dementia
📈 PositiveBenzinga•Nov 5, 2025, 01:31 PM
Nexalin Technology Receives Approval To Sell Its Gen-2 Console Device In Israel
📈 PositiveBenzinga•Oct 30, 2025, 12:31 PM
Nexalin Technology Announces Three Independent Peer-Reviewed Clinical Studies, Along With Internal Data, Show That Its 15 mA Gen-2 Nexalin DIFS Technology Can Improve Cognition, Restore Brain Activity, And Enhance Neuron Connectivity In Patients With Alzheimer's Disease
📈 PositiveBenzinga•Oct 21, 2025, 01:03 PM
Nexalin Technology Enters Amendment No. 2 To Equity Distribution Agreement; Amendment Increases Maximum Shares Offering Price To $10M
➖ NeutralBenzinga•Oct 15, 2025, 09:16 PM
Nexalin Technology shares are trading higher after the company announced additional results in alzheimer's disease with the Gen-2 SYNC neurostimulation device.
📈 PositiveBenzinga•Oct 8, 2025, 02:45 PM
Nexalin Announces Publication Of Additional Clinical Data In Radiology Showing Proprietary 15 mA Gen-2 Nexalin DIFS Technology Improves Cognitive Performance And Enhances Brain Network Connectivity In AD Patients
📈 PositiveBenzinga•Oct 8, 2025, 01:20 PM
Nexalin Secures 15-Yr US Design Patent For HALO Clarity Neuromodulation Device
📈 PositiveBenzinga•Oct 8, 2025, 12:38 PM
Nexalin Technology Announces US Patent Providing 15 Years Of Design Protection For HALO Clarity Device
📈 PositiveBenzinga•Sep 25, 2025, 12:32 PM
Nexalin Technology slides after pricing $5M stock offering
📉 NegativeSeeking Alpha•May 5, 2025, 12:31 PM
Frequently Asked Questions about NXL
What is NXL's current stock price?
Nexalin Technology, Inc. (NXL) is currently trading at $0.83 per share. The stock has moved +3.29% today.
What is the analyst price target for NXL?
No analyst price targets are currently available for this stock.
What sector is Nexalin Technology, Inc. in?
Nexalin Technology, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is NXL's market cap?
Nexalin Technology, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does NXL pay dividends?
No, Nexalin Technology, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLGN
CollPlant Biotechnologies Ltd.
$1.52
Mkt Cap: $0.0B
ENLV
Enlivex Therapeutics Ltd.
$0.83
Mkt Cap: $0.0B
HBIO
Harvard Bioscience, Inc.
$0.75
Mkt Cap: $0.0B
IINN
Inspira Technologies Oxy B.H.N. Ltd.
$1.02
Mkt Cap: $0.0B
MODD
Modular Medical, Inc.
$0.34
Mkt Cap: $0.0B
NRXS
NeurAxis, Inc.
$3.22
Mkt Cap: $0.0B
RBOT
Vicarious Surgical Inc.
$2.17
Mkt Cap: $0.0B
RVP
Retractable Technologies, Inc.
$0.82
Mkt Cap: $0.0B
SCYX
SCYNEXIS, Inc.
$0.63
Mkt Cap: $0.0B
XCUR
Exicure, Inc.
$5.92
Mkt Cap: $0.0B
Explore stocks similar to NXL for comparison